Schizophrenia Research Forum: Animal Models
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Print this page
Animal Models:Drug-Induced
Name DA-related behavior Gating Cognitive behavior Social behavior Molecular and/or Morphological Signature Response to APD
Basolateral Amygdala Picrotoxin Infusion Rat         GABA antagonism in BLA decreases GAD67 in HPC, GABA antagonism in BLA increases HPC LTP  
Ceftriaxone-Induced Glutamate Transporter Upregulation Rat   Impairs PPI.        
CHX Induced Glutathione Depletion     Disrupted short-term spatial memory   Reduced striatal and cortex glutathione levels  
Disinhibition of Ventral Hippocampus Rat Increased locomotor activity Disrupted PPI Disrupted fear conditioning   Increased accumbens and cortex dopamine Haloperidol and clozapine block hyperactivity but no effect on PPI deficit
Methamphetamine Treatment-Chronic   Disrupted PPI Impaired recognition memory   Increased TUNEL-positive cells in mPFC Memory impairment blocked by GABA(B) agonist, PPI disruption and TUNEL-positive cell counts blocked by olanzapine and risperidone
Neonatal EGF Treatment, Rodent Increased locomotor activity Impaired PPI   Reduced social behavior Enhanced cAMP response to D2R activation Haloperidol reduced motoric activity, clozapine improved social deficit
NMDA Receptor Antagonist Rx (MK801, PCP, Ketamine)-Acute, Rodent Increases locomotor activity and stereotopy, ataxia Disrupted PPI 1 day after PCP, and 15 minutes after PCP, but not 7 or 28 days later, abnormal latent inhibition Decreased working memory, disrupted fear conditioning, long-term spatial memory deficits, impaired passive-avoidance, recognition memory deficit Impaired social interaction Impaired LTP, decreased AMPA receptor density Enhanced locomotor responses blocked by APD, glycine transporter-1 inhibition rescues LTP, PPI disruption attenuated by admatine, glycine, D-serine, not D-cycloserine, fear conditioning disruption prevented by clozapine, but not haloperidol, LI abnormalities reversed by risperidone and M100907, passive avoidance impairment reversed by lurasidone, recognition memory deficit reversed by clozapine and D-serine, but not haloperidol
Subchronic Perinatal PCP Treatment Rat Increased sensitivity to PCP-induced locomotor activity Long-lasting deficits in PPI Spatial memory deficits (sex dependent)   Cortical apoptosis; increased expression of NMDAR subunits NR1 and NR2A in the frontal cortex; altered neuregulin 1/erbB4 expression and activation in the prefrontal cortex PPI deficits and increased sensitivity to PCP-induced locomotor activity were ameloriated by treatment with risperidone (0.25 mg/kg) and olanzapine (1.0 mg/kg)